Research Area
CAR-T Therapy (Cancer Immunotherapy) The goal of the lab is to improve CAR T cell therapy by making them more effective in killing cancer cells and/or preventing the toxicities associated with treatment. This is achieved by performing translation studies in the lab, applying the findings to patients in the clinic, and analyzing how patients respond to CAR T cell treatment using correlative studies. Laboratory research explores the basic biology of CAR-T function, improves CAR-T efficacy and expands their use to different tumor types.
Team Description
The Maus lab is currently composed of upwards of 25 researchers, including MD, MD-PhD, and post doctoral fellows, PhD and Master's students, staff scientists and technicians. Dr. Maus is also a co-mentor to graduate students and hosts summer, undergraduate and graduate students on rotations throughout the year.
Team Members
Team Show
Publications
1.Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.Haradhvala, Leick, Maurer, Gohil et al,Nature Medicine 2022
2.CAR T cell killing requires the IFNγR pathway in solid but not liquid tumors.Larson et al, Nature 2022
3.Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.Leick et al, Cancer Cell 2022
4.Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.Frigault et al, Blood Advances 2022
5.Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.Bailey et al, Blood Cancer Discovery 2022
6.Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.Jan et al, Science Translational Medicine 2021
7.Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).Wehrli et al, Journal for Immunotherapy of Cancer 2022